June 8, 2017August 24, 2022
Keytruda Improves Survival in Advanced Melanoma Patients Compared to Yervoy, Phase 3 Trial Shows
News
Patients with unresectable or metastatic melanoma who were treated with Keytruda (pembrolizumab) in a pivotal clinical trial showed superior and sustained time ... Read more
June 6, 2017
New Evidence Presented on Accuracy of DecisionDx-Melanoma Prognosis Test
News
Castle Biosciences presented three abstracts on the validity of using its 31-Gene Expression Profile (GEP) Test for melanoma prognosis at the ... Read more
June 1, 2017June 2, 2017
Biothera to Present Detailed Design of Combo Therapy Study for Melanoma, Breast Cancer
News
Biothera Pharmaceuticals will present the detailed study design of the IMPRIME-1 clinical trial at the upcoming 2017 ASCO Annual Meeting June 2-6 in ... Read more
May 30, 2017
Researchers Provide New Insights into Melanoma Immune Resistance
News
A new study presents detailed information into the processes used by cancer cells to evade and resist the immune response. Researchers studied ... Read more
May 25, 2017May 25, 2017
New Clinical Trial Underway for Treatment of Advanced Melanoma
News
A new clinical trial is underway assessing the addition of the first-in-class AXL kinase inhibitor, BGB324, to standard of care treatment for patients with ... Read more
May 23, 2017May 23, 2017
Skin Cancer Awareness Month Brings Sun Safety to Schools
News
Educating people of all ages, particularly children, about the dangers of sun exposure is urgent to preventing the increased prevalence ... Read more
May 18, 2017
First Patient Enrolled in ONCOS-102, Keytruda Combo Trial for Advanced Melanoma
News
The first patient has been enrolled in Targovax‘s pilot clinical trial for advanced or unresectable melanoma patients whose cancer progressed after treatment ... Read more
May 16, 2017
ImmunoPulse IL-12 and Keytruda Combo Therapy to be Tested in Phase 2 Trial
News
The combination of ImmunoPulse IL-12 and the anti-PD-1 therapy Keytruda (pembrolizumab) soon will be tested in a Phase 2 trial for treatment ... Read more
May 11, 2017
Binimetinib Improves Progression-free Survival of Certain Melanoma Patients in Phase 3 Trial
News
Adding the small molecule MEK inhibitor binimetinib to the BRAF inhibitor encorafenib was safe and significantly prolonged the time to disease progression ... Read more
May 9, 2017May 9, 2017
Melanoma Scientist Among 6 in NYC Awarded Prestigious Research Prize
News
The Pershing Square Sohn Cancer Research Alliance has announced the six winners of the fourth edition of the annual Pershing ... Read more
May 4, 2017
Castle’s Gene Test Shows Accuracy in Predicting Recurrence, Spread of Head and Neck Melanoma
News
Castle Biosciences’ DecisionDx-Melanoma test can be used to accurately predict cancer recurrence and metastasis in patients with head and neck melanoma, ... Read more
April 25, 2017
IMP321, Keytruda Combo Trial Receives OK to Open Last Patient Group
News
Prima Biomed, an Australian biotechnology company developing immunotherapies for cancer and autoimmune diseases, announced it has received approval for the ... Read more

June 8, 2017August 24, 2022

Keytruda Improves Survival in Advanced Melanoma Patients Compared to Yervoy, Phase 3 Trial Shows

News

Patients with unresectable or metastatic melanoma who were treated with Keytruda (pembrolizumab) in a pivotal clinical trial showed superior and sustained time to disease progression when compared to those treated with Yervoy (ipilimumab). ... Read more

June 6, 2017

New Evidence Presented on Accuracy of DecisionDx-Melanoma Prognosis Test

News

Castle Biosciences presented three abstracts on the validity of using its 31-Gene Expression Profile (GEP) Test for melanoma prognosis at the American Society of Clinical Oncology (ASCO) 2017 annual meeting June 2-6 ... Read more

June 1, 2017June 2, 2017

Biothera to Present Detailed Design of Combo Therapy Study for Melanoma, Breast Cancer

News

Biothera Pharmaceuticals will present the detailed study design of the IMPRIME-1 clinical trial at the upcoming 2017 ASCO Annual Meeting June 2-6 in Chicago. The trial is currently enrolling advanced melanoma or triple ... Read more

May 30, 2017

Researchers Provide New Insights into Melanoma Immune Resistance

News

A new study presents detailed information into the processes used by cancer cells to evade and resist the immune response. Researchers studied how the interferon gamma pathway guides cell signaling in melanoma cells by mapping the molecules and ... Read more

May 25, 2017May 25, 2017

New Clinical Trial Underway for Treatment of Advanced Melanoma

News

A new clinical trial is underway assessing the addition of the first-in-class AXL kinase inhibitor, BGB324, to standard of care treatment for patients with advanced unresectable or metastatic melanoma. The Phase 1/2 clinical trial ... Read more

May 23, 2017May 23, 2017

Skin Cancer Awareness Month Brings Sun Safety to Schools

News

Educating people of all ages, particularly children, about the dangers of sun exposure is urgent to preventing the increased prevalence of melanoma and skin cancer, the Skin Cancer Foundation reported in a press release. The ... Read more

May 18, 2017

First Patient Enrolled in ONCOS-102, Keytruda Combo Trial for Advanced Melanoma

News

The first patient has been enrolled in Targovax‘s pilot clinical trial for advanced or unresectable melanoma patients whose cancer progressed after treatment with checkpoint inhibitors. The study is being conducted at Memorial ... Read more

May 16, 2017

ImmunoPulse IL-12 and Keytruda Combo Therapy to be Tested in Phase 2 Trial

News

The combination of ImmunoPulse IL-12 and the anti-PD-1 therapy Keytruda (pembrolizumab) soon will be tested in a Phase 2 trial for treatment of metastatic melanoma. The study, called PISCES, is part of ... Read more

May 11, 2017

Binimetinib Improves Progression-free Survival of Certain Melanoma Patients in Phase 3 Trial

News

Adding the small molecule MEK inhibitor binimetinib to the BRAF inhibitor encorafenib was safe and significantly prolonged the time to disease progression or death in patients with BRAF-mutant advanced, unresectable, or metastatic ... Read more

May 9, 2017May 9, 2017

Melanoma Scientist Among 6 in NYC Awarded Prestigious Research Prize

News

The Pershing Square Sohn Cancer Research Alliance has announced the six winners of the fourth edition of the annual Pershing Square Sohn Prize for Young Investigators in Cancer Research, one ... Read more

May 4, 2017

Castle’s Gene Test Shows Accuracy in Predicting Recurrence, Spread of Head and Neck Melanoma

News

Castle Biosciences’ DecisionDx-Melanoma test can be used to accurately predict cancer recurrence and metastasis in patients with head and neck melanoma, the company announced. Studies found that the accuracy of the ... Read more

April 25, 2017

IMP321, Keytruda Combo Trial Receives OK to Open Last Patient Group

News

Prima Biomed, an Australian biotechnology company developing immunotherapies for cancer and autoimmune diseases, announced it has received approval for the third cohort of its Phase 1 melanoma trial (NCT02676869), TACTI-mel. ... Read more